NEW YORK (GenomeWeb) - Guardant Health said today that it has entered a definitive agreement to acquire Bellwether Bio, a privately held firm formed two years ago to advance a method for early blood-based cancer detection that relies on detecting epigenetic signals in circulating cell free DNA.